Predictive factors for response and survival of gefitinib-treated locally advanced or metastatic non-small cell lung cancer patients: A retrospective analysis of two phase II clinical trials

Chinese Journal of Cancer

Volumn 28, Issue 6, 2009, Pages

  Zhao, Yuan Yuan ^a   Zhang, Yang ^a   Zhao, Hong Yun ^a   Wu, Jing Xun ^a   Jiang, Wei ^a   Xue, Cong ^a   Zhang, Li ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Chemotherapy; Efficay; Gefitinib; Lung neoplasm; Non small cell; Predictive factors; Survival

Indexed keywords

GEFITINIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CHINA; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORNING DOSAGE; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTION; RASH; SURVIVAL RATE; SURVIVAL TIME;

EID: 79955776171     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003 [J]. CA Cancer J Clin, 2003, 53 (1): 5-26.
2. Fossella FV, Lee JS, Hong WK. Management strategies for recurrent non-small cell lung cancer [J]. Semin Oncol, 1997, 24(4): 455-462.
3. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy [J]. J Clin Oncol, 2000, 18 (10): 2095-2103.
4. Kaneda H, Tamura K, Kurata T, et al. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer [J]. Lung cancer, 2004, 46 (2): 247-254.
5. Park K, Goto K. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer [J]. Curr Med Res Opin, 2006, 22(3): 561-573.
6. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J]. N Engl J Med, 2004, 350(21): 2129-2139.
7. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer [J]. J Natl Cancer Inst, 2005, 97 (9): 643-655.
8. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study [J]. J Clin Oncol, 2005, 23 (28): 6838-6845.
9. Guan ZZ, Zhang L, Li LY, et al. Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small cell lung cancer: a clinical trial [J]. Ai Zheng, 2005, 24(8): 980-984. [in Chinese]
10. Zhang Y, Zhang L, Xu F, et al. Efficacy of gefitinib on advanced non-small cell lung cancer in expanded access program (EAP) [J]. Ai Zheng, 2006, 25 (12): 1561-1564. [in Chinese]
11. Su WP, Yang CH, Yu CJ, et al. Gefitinib treatment for non-small cell lung cancer-a study including patients with poor performance status [J]. J Formos Med Assoc, 2005, 104 (8): 557-562.
12. Chang GC, Chen KC, Yang TY, et al. Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status [J]. Invest New Drugs, 2005, 23(1): 73-77.
13. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] [J]. J Clin Oncol, 2003, 21 (12): 2237-2246.
14. Chang GC, Tsai CM, Chen KC, et al. Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients [J]. J Thorac Oncol, 2006, 1 (6): 520-525.
15. Lee DH, Han JY, Yu SY, et al. The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study [J]. J Thorac Oncol, 2006, 1 (9): 965-971.
16. Clark GM. Prognostic factors versus predictive factors: examples from a clinical trial of erlotinib [OL]. Molecular oncology, 2008, 1: 406-412.
17. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer [J]. J Clin Oncol, 2005, 23 (28): 6829-6837.
18. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence [J]. J Clin Oncol, 2005, 23(11): 2513-2520.
19. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib [J]. J Clin Oncol, 2005, 23 (11): 2493-2501.
20. Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/ INTACT gefitinib trials [J]. J Clin Oncol, 2005, 23 (31): 8081-8092.
21. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome [J]. N Engl J Med, 2005, 353(2): 133-144.
22. Hirsch FR, Varella-Garcia M, Bunn PA, Jr., et al. Molecular predictors of outcome with gefitinib in a phase! placebo-controlled study in advanced non-small-cell lung cancer [J]. J Clin Oncol, 2006, 24(31): 5034-5042.
23. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib [J]. J Clin Oncol, 2005, 23 (25): 5900-5909.
24. Mok T, Wu YL, Thongprasert S, et al. Phase III, randomized, open-label, first-line study of gefitinib vs. carboplatin/paclitaxol in clinically selected patients with advanced non-small-cell lung cancer (IPASS) [J]. Ann Oncol, 2008, 19 (Suppl 8): viii1-viii4.
25. Kurata T, Matsuo K, Takada M, et al. Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer? [J]. J Thorac Oncol, 2006, 1 (7): 684-691.